Karyopharm Therapeutics Inc (KPTI)

NASDAQ
10.32
-0.23(-2.18%)
After Hours
10.42
+0.10(+0.97%)
- Real-time Data
  • Volume:
    1,504,512
  • Bid/Ask:
    10.32/10.65
  • Day's Range:
    10.16 - 10.73

KPTI Overview

Prev. Close
10.55
Day's Range
10.16-10.73
Revenue
113.2M
Open
10.72
52 wk Range
7.78-20.99
EPS
-2.72
Volume
1,504,512
Market Cap
774.96M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,745,497
P/E Ratio
-
Beta
0.23
1-Year Change
-38.2%
Shares Outstanding
75,092,567
Next Earnings Date
Aug 10, 2021
What is your sentiment on Karyopharm Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Karyopharm Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyBuyStrong Sell
Technical IndicatorsBuyStrong BuyBuyStrong BuyStrong Sell
SummaryNeutralBuyBuyStrong BuyStrong Sell

Karyopharm Therapeutics Inc Company Profile

Karyopharm Therapeutics Inc Company Profile

Employees
432

Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.

Read More
  • Should reach USD 25 fairvalue by Mar
    1
    • eanings 🚀🚀🚀
      0
      • REVENUE BEAT 33.51M OVER EST 28.41M, undervalued based on upgrades - reported by Reuters June 23: H.C. Wainwright raises target price to $41 from $40, Jefferies raises target price to $35 from $34, JP Morgan raises target price to $37 from $31, RBC raises target price to $30 from $28, SVB Leerink raises target price to $31 from $29
        0
        • bullish
          0
          • KPTI. We like this stock and see it doubling from here in back half of 2020. Last: $18.99.
            1
            • What is the target?
              0
              • 20.00 It just rose 70 % ! In one Day alone.... I expect a Big Discount. They knew what they were up too! That's why they drove the price up so astronomically for the OFFERING! Happens all the time...and we get the Shaft!
                0
              • is it good to buy today?
                0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.